Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.83 USD | 0.00% | +4.27% | -87.57% |
Financials (USD)
Sales 2024 * | 97.16M | Sales 2025 * | - | Capitalization | 124M |
---|---|---|---|---|---|
Net income 2024 * | -206M | Net income 2025 * | -93M | EV / Sales 2024 * | 0.38 x |
Net cash position 2024 * | 87.38M | Net cash position 2025 * | 62.5M | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-0.61
x | P/E ratio 2025 * |
-1.39
x | Employees | 384 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 85.33% |
Latest transcript on Amylyx Pharmaceuticals, Inc.
1 week | +4.27% | ||
Current month | +1.10% | ||
1 month | -7.58% | ||
3 months | -88.48% | ||
6 months | -84.84% | ||
Current year | -87.57% |
Managers | Title | Age | Since |
---|---|---|---|
Justin Klee
FOU | Founder | 34 | 12-12-31 |
Josh Cohen
FOU | Founder | 33 | 12-12-31 |
Jim Frates
DFI | Director of Finance/CFO | 56 | 20-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
George Milne
CHM | Chairman | 80 | 14-12-31 |
Kari Firestone
BRD | Director/Board Member | - | 23-03-15 |
Paul R. Fonteyne
BRD | Director/Board Member | 63 | 21-03-28 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.14% | 0 M€ | 0.00% | - | |
0.09% | 234 M€ | +5.72% | - | |
0.04% | 2 M€ | -.--% | ||
0.02% | 9 M€ | +11.05% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-17 | 1.83 | 0.00% | 1,222,822 |
24-05-16 | 1.83 | +0.55% | 777,311 |
24-05-15 | 1.82 | -2.67% | 1,097,460 |
24-05-14 | 1.87 | +2.75% | 1,572,136 |
24-05-13 | 1.82 | +3.70% | 1,351,129 |
Delayed Quote Nasdaq, May 17, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-87.57% | 124M | |
-2.32% | 90.45B | |
+3.68% | 41.45B | |
-10.90% | 33.57B | |
+58.05% | 25.73B | |
-19.56% | 14.73B | |
-9.06% | 12.82B | |
-11.34% | 11.7B | |
-43.53% | 11.44B | |
+3.75% | 8.79B |
- Stock Market
- Equities
- AMLX Stock